Glycosylation is a complex and critical aspect of most therapeutic proteins that must be well characterized and monitored throughout product development and commercialization. RapiFluor-MS can be used to dramatically reduce sample preparation times and complexity, to enhance FLR sensitivity, and to dramatically improve MS sensitivity.
In this application note, we present the combined use of RapiFluor-MS labeling reagent, ACQUITY UPLC H-Class Bio System, and serial fluorescence/ACQUITY QDa Mass Detector for the monitoring of released N-glycan profiles from IgGs. Overall, this new workflow allows scientists to rapidly prepare samples, from glycoprotein to analysis in 30 minutes.
By improving glycan MS sensitivity, RapiFluor-MS labeling permits the use of mass detection with the ACQUITY QDa and thereby affords greater confidence in peak monitoring across the range of structures encountered during biopharmaceutical development.
|Download pdf (720005352en)||1483.12kB|